Emergence of dalbavancin, vancomycin, and daptomycin cross-resistance in MRSA during long-term LVAD suppression with vancomycin followed by dalbavancin: genomic insights and synergy with cefadroxil
β
Just Accepted
π https://bit.ly/4azpqPJ
Emergence of dalbavancin, vancomycin, and daptomycin cross-resistance in MRSA during long-term LVAD suppression with vancomycin followed by dalbavancin: genomic insights and synergy with cefadroxil
β
Just Accepted
π https://bit.ly/4azpqPJ
Our ID division is well represented at #IDWeek2025, come find us at a talk or a poster!
@idweek.bsky.social @idsainfo.bsky.social #IDSky
blog.unmc.edu/infectious-d...
Evaluation of the safety of cefazolin monotherapy in outpatient parenteral antimicrobial therapy at a large academic medical center
β
Just Accepted
#IDSky
π https://bit.ly/3Kry6gk
IDSA Foundation board member Dr. Jasmine Marcelin was in DC this week for #ALC54, an event hosted by the Congressional Black Caucus Foundation. Dr. Marcelin spoke on a panel, highlighting IDSA's efforts to diversify the ID workforce, advance health equity and expand access to care.
Interested in learning about how a UTI order panel w/ clinical & laboratory reflex criteria can potentially impact UCx rates & CAUTIs? Join Esther Banker, PharmD & Yi Guo, PharmD, BCIDP from Montefiore Pharmacy residency in our latest SIDP Journal Club series (sidp.org/BCIDP), worth 1.5h of credit!
Are you a trainee in Nebraska with an interest in Infectious Diseases?
Submit your research or interesting case report to the annual Nebraska ID Society meeting trainee abstract competition! #IDSky @unmccom.bsky.social
Learn more and submit your abstract here:
forms.office.com/r/69Q95n4KK9
Congrats to Dr. Keintz, @bryanidpharmd.bsky.social, and Dr. Van Schooneveld on their recent publication in @ashejournal.bsky.social:
"Utility of urine culture in men with uncomplicated cystitis in ambulatory settings"
#IDSky #UTISky
www.cambridge.org/core/journal...
Nice paper this week highlighting again the uselessness of serial ESR/CRP for many ID indications.
Really pleased to see an increasing focus in our OPAT community on diagnostic stewardship, working to decrease the number of unnecessary labs ordered, on behalf of both patients and OPAT personnel!
Dr. Keintz is interviewed in this @contagionlive.bsky.social article about her most recent paper in @ashejournal.bsky.social
Read the paper here:
www.cambridge.org/core/journal...
@bryanidpharmd.bsky.social #IDSky #UTISky
S.lugdunensis is the Sammy Sosa of the SOSA π₯
I'm the only one from the group on BlueSky!?? π€ Anyway, this one was 95% Mackenzie Keintz, so particular shout-out to her!
@unmc.bsky.social ID: We describe the development and validation of an electronically-captured appropriate antibiotic use metric for ambulatory UTIs using coding data bit.ly/3Ws3Ogm
Whelp. I decided to hop on the bandwagon & here I am!
Depending on underlying indication and acuity, I'd start with AmB, or an AmB combo. One other FDA-approved option you could consider is ibrexafungerp. The only trial for IC I know of used 750mg BID x 2d, then 750mg daily through EOT (~2wks in the study). Experience outside VVC is very limited.
Scattergram for Aspergillus fumigatus isavuconazole MIC (mg/L) vs voriconazole MIC (mg/L) using CLSI MIC breakpoint interpretive criteria. S, susceptible; I, intermediate; R, resistant
ππ«Analysis of a collection of A. fumigatus from a global surveillance program:
Voriconazole has excellent parameters to be used as a surrogate for isavuconazole susceptibility in situations where isavuconazole susceptibility testing is not feasible
#idsky
journals.asm.org/doi/10.1128/...
Welcome! The positives outweigh the current tradeoffs for the most of us. Really enjoy driving my Ioniq 5.
There definitely is, we are apparently just incapable of choosing it. Pharmacist-on-pharmacist crime, and this unfortunately isn't the only example... ACPE, MPJE, etc. A big loss to trainees when paperwork burnout robs them of superlative mentorship those like you are otherwise eager to provide.
Not enough! Pseudo less often mainly because the data are very limited for more complicated cystitis or pyelo where those are more common, but underutilized vs OPAT for Enterobacterales where resistance precludes or complicates oral therapy.
That's 1-2 articles PER PATIENT, right? I thought so... just doesn't make sense otherwise. Thanks! π
Thanks very much, these are endlessly helpful for recreating the community!